

Freedom of Information Request: Our Reference CTMUHB_321_23

You asked:

We are seeking to understand the initiation of patient treatment with Nivolumab and some additional products in different types of cancer. We would greatly appreciate if you could answer the following questions:

Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

- Ipilimumab (monotherapy)
- Nivolumab (monotherapy)
- Nivolumab AND Ipilimumab (combination)
- Pembrolizumab
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of renal cell carcinoma?

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Avelumab + Axitinib

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q3. In the past 3 months, how many patients have been initiated* on the following agents for the treatment of gastric, gastro-oesophageal junction or oesophageal cancer:

- Nivolumab monotherapy or in combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Our response:

We can confirm that Cwm Taf Morgannwg University Health Board does not hold the information you require. The Health Board does not administer the treatments listed. Cwm Taf Morgannwg residents receive cancer treatments from the Velindre Cancer Centre or Singleton Hospital (Oncology) based on their postcode.

Therefore, you will need to redirect your request to Velindre/Singleton, who provide these services to Cwm Taf Morgannwg residents.

Contact details are shown below in the following links:

For Velindre:

[Freedom of information contacts - Velindre University NHS Trust](#)

For Singleton Hospital – Swansea Bay University Health Board:

[Freedom of information - Swansea Bay University Health Board \(nhs.wales\)](#)